Big Money Are Betting On Acorda Therapeutics Inc (NASDAQ:ACOR), Sentiment at 1.45

November 10, 2018 - By Ricky Cave

Acorda Therapeutics, Inc. (NASDAQ:ACOR) Corporate Logo

“Big money” Positions

In Q2 2018 Acorda Therapeutics Inc (NASDAQ:ACOR) big money sentiment increased to 1.45, revealed SEC filings. So its up 0.02, from 2018Q1’s 1.43. 90 investment managers increased or started new stock positions, while 62 reduced and sold their stock positions in Acorda Therapeutics Inc so the sentiment is more positive. These funds own 47.68 million shares, that’s down from 48.53 million shares in 2018Q1. Funds holding Acorda Therapeutics Inc in top 10 changed to 0 from 0 for the same number . In total 16 funds closed positions, 46 reduced and 56 increased. Also 34 funds bought new Acorda Therapeutics Inc stakes.

Most Acorda Therapeutics Inc Shareholders

Partner Fund Management L.P. owns 2.16 million shares in Acorda Therapeutics Inc as of Q2 2018. Acorda Therapeutics Inc’s shareholder Malaga Cove Capital Llc owns 52,163 shares as of Q2 2018. Spark Investment Management Llc reported 411,000 shares. The California-based fund Partner Investment Management L.P. have invested about 0.64% of the active investment manager’s stock portfolio in Acorda Therapeutics Inc. The Maryland-based fund Hussman Strategic Advisors Inc. holds 75,000 shares or 0.58% of their equity exposure.

Acorda Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and commercializes therapies for neurological disorders in the United States.The firm is worth $947.30 million. The firm markets Ampyra , an oral drug to improve walking in patients with multiple sclerosis (MS); Zanaflex capsules and tablets for the management of spasticity; and Qutenza, a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia.Last it reported negative earnings. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas.

Ticker’s shares touched $19.95 during the last trading session after 3.30% change.Acorda Therapeutics, Inc. has volume of 384,469 shares. Since November 10, 2017 ACOR has declined 20.26% and is downtrending. ACOR underperformed by 35.88% the S&P500.

Deutsche Bank & Trust Ag holds 0% of its capital in Acorda Therapeutics, Inc. (NASDAQ:ACOR) for 162,130 shs. Hbk Investments Limited Partnership reported 28,100 shs or 0.01% of all its holdings. 14,539 were accumulated by Metropolitan Life Com New York. Price T Rowe Assocs Incorporated Md reported 0% in Acorda Therapeutics, Inc. (NASDAQ:ACOR). State Board Of Administration Of Florida Retirement Systems reported 0% stake. Whittier Trust invested 0.06% in Acorda Therapeutics, Inc. (NASDAQ:ACOR). Wells Fargo & Communication Mn has invested 0% in Acorda Therapeutics, Inc. (NASDAQ:ACOR). Royal Comml Bank Of Canada, Ontario – Canada-based fund reported 389 shs. Nebraska-based Ameritas Ptnrs Incorporated has invested 0.01% in Acorda Therapeutics, Inc. (NASDAQ:ACOR). Fincl Bank Of Montreal Can owns 0% invested in Acorda Therapeutics, Inc. (NASDAQ:ACOR) for 1,062 shs. Geode Cap Mgmt Ltd Liability has 0% invested in Acorda Therapeutics, Inc. (NASDAQ:ACOR) for 500,900 shs. Moreover, State Of Tennessee Treasury Department has 0% invested in Acorda Therapeutics, Inc. (NASDAQ:ACOR). Voya Investment Ltd Liability Com holds 0% in Acorda Therapeutics, Inc. (NASDAQ:ACOR) or 37,243 shs. Pnc Financial Services Grp Inc has invested 0% in Acorda Therapeutics, Inc. (NASDAQ:ACOR). The Connecticut-based Aqr Cap Mngmt Limited has invested 0% in Acorda Therapeutics, Inc. (NASDAQ:ACOR).

Acorda Therapeutics, Inc. had 20 selling transactions and 0 insider purchases since May 15, 2018. This’s net activity of $46.57 million. On Monday, July 2 the insider BLANK BURKHARD sold $148,050. LAWRENCE DAVID had sold 25,000 shs worth $704,783 on Thursday, June 7. RAUSCHER STEVEN M sold 10,000 shs worth $245,853. Sabella Lauren M sold $853,125 worth of stock. SMITH IAN F sold $785,568 worth of Acorda Therapeutics, Inc. (NASDAQ:ACOR) or 25,000 shs on Friday, June 15. On Friday, May 25 a trade for 42,615 shs valued at $1.03M was made by Hindman Andrew A..

Acorda Therapeutics, Inc. (NASDAQ:ACOR) Ratings Coverage

In total 3 analysts cover Acorda Therapeutics (NASDAQ:ACOR). “Buy” rating has 1, “Sell” are 0, while 2 are “Hold”. 33% are bullish. 5 are the (NASDAQ:ACOR)’s analyst reports since May 30, 2018 according to StockzIntelligence Inc. On Wednesday, May 30 the stock of Acorda Therapeutics, Inc. (NASDAQ:ACOR) has “Buy” rating given by H.C. Wainwright. In Friday, October 5 report Stifel Nicolaus maintained the stock with “Hold” rating. On Tuesday, August 7 the stock of Acorda Therapeutics, Inc. (NASDAQ:ACOR) earned “Hold” rating by Stifel Nicolaus. In Monday, June 11 report H.C. Wainwright maintained the stock with “Buy” rating.

More recent Acorda Therapeutics, Inc. (NASDAQ:ACOR) news were brought out by Nasdaq.com, Nasdaq.com and Seekingalpha.com. The first one has “Investor Expectations to Drive Momentum within SunOpta, Acorda Therapeutics, Sapiens International Corporation NV …” as a title and was brought out on October 17, 2018. The next is “Detailed Research: Economic Perspectives on KB Home, Lennox International, CorVel, Acorda Therapeutics, PROS …” on November 08, 2018. And last was brought out on October 31, 2018, called “Acorda Therapeutics beats by $0.31, beats on revenue”.

Acorda Therapeutics, Inc. (NASDAQ:ACOR) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.